Administering (+)-SJ733 to mice engineered to lack immune response (NOD-scid IL2Rγnull) and infected with P. falciparum leads to a swift eradication of the parasites, showing an 80% reduction within the first 24 hours and achieving a state where they are undetectable by the 48-hour mark. In a model using the NOD-scid IL2Rγnull mice, when given as four successive daily oral doses, (+)-SJ733 demonstrated remarkable potency and effectiveness against P. falciparum 3D70087/N9 in vivo. It achieved a 90% effective dose (ED90 of 1.9 mg/kg) and drug exposure [area under the curve at ED90 (AUCED90), 1.5 μM⋅h], outperforming artesunate (11.1 mg/kg; AUCED90 unspecified), chloroquine (4.3 mg/kg; AUCED90 3.1 μM⋅h), and pyrimethamine (0.9 mg/kg; AUCED90 5. μM⋅h) in this specific experiment. Following administration of the ED90 dosage, the concentration of (+)-SJ733 in the blood remained higher than the average in vitro EC90 for a duration of 6 to 10 hours post-dose^[1].

(+)-SJ733 is an anti-malaria agent which can also inhibit Na+-ATPase PfATP4^[1].

Acting as an anti-malarial compound, (+)-SJ733 also serves to impede the Na+-ATPase PfATP4 enzyme^[1]. The agent attaches itself to a unique receptor on P. falciparum-infected red blood cells, demonstrating a binding affinity equal to its inhibitory effect on growth (kd=50 nM). In comprehensive in vitro analyses and various in vivo dose-regimen studies, (+)-SJ733 revealed no significant safety or tolerability issues across any tested dosages in preclinical models, showcasing a no observed adverse effect level and a maximum tolerated dose exceeding 240 mg/kg from a study over seven days of repeated dosing in rats. Consequently, (+)-SJ733 is projected to possess a safety buffer of at least 43 times^[1].